Drug Trial Radar · NCT06687369
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)
Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
726
Planned (sponsor's estimate)
Start
Dec 30, 2024
Primary completion
Aug 31, 2026
Study completion Sep 2027
Sponsor
- Lead sponsor
- mAbxience Research S.L.Industry
- Sponsor type
- Industry
- First posted
- Nov 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, multicenter, multinational, double-blind, integrated pharmacokinetics (PK) and efficacy similarity study to compare the PK, efficacy, safety, and immunogenicity of MB12 versus Keytruda® in combination with pemetrexed-platinum chemotherapy as first-line treatment in patients with metastatic non-squamous NSCLC.
Conditions
- Non Squamous Non Small Cell Lung Cancer
Interventions
MB12 (Proposed Pembrolizumab Biosimilar)Drug
200mg IV, every 3 weeks on Day 1
EU-sourced Keytruda®Drug
200mg IV, every 3 weeks on Day 1
US-sourced Keytruda®Drug
200mg IV, every 3 weeks on Day 1
PemetrexedDrug
500 mg/m2 IV, every 3 weeks on Day 1
CarboplatinDrug
Area under the curve (AUC) 5 IV, every 3 weeks on Day 1 for 4 cycles.
CisplatinDrug
75 mg/m2 IV, every 3 weeks on Day 1 for 4 cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- To demonstrate the pharmacokinetic (PK) bioequivalence of MB12, EU-sourced Keytruda® and US-sourced Keytruda® in combination with chemotherapyTime frame: Week 1 - Week 24
- To demonstrate the efficacy equivalence of MB12 and Keytruda® in combination with chemotherapy administered as first-line treatment in patients with advanced/metastatic non-squamous NSCLC (any PD-L1 expression type).Time frame: Week 1 - Week 24
Locations
173 sites in 24 countries. Site status is shown where the registry gives one.
Site 101001
Yerevan, Armenia
Site 101002
Yerevan, Armenia
Site 101003
Yerevan, Armenia
Site 101004
Yerevan, Armenia
Site 103001
Sarajevo, Bosnia and Herzegovina
Site 103002
Tuzla, Bosnia and Herzegovina
Site 103003
Zenica, Bosnia and Herzegovina
Site 301014
Barretos, Brazil
Site 301026
Belém, Brazil
Site 301002
Belo Horizonte, Brazil
Site 301023
Bento Gonçalves, Brazil
Site 301006
Blumenau, Brazil
Site 301019
Caxias do Sul, Brazil
Site 301015
Curitiba, Brazil
Site 301028
Curitiba, Brazil
Site 301024
Florianópolis, Brazil
Site 301010
Fortaleza, Brazil
Site 301011
Ijuí, Brazil
Site 301008
Itajaí, Brazil
Site 301012
Jaú, Brazil
Site 301018
Natal, Brazil
Site 301003
Porto Alegre, Brazil
Site 301005
Porto Alegre, Brazil
Site 301007
Porto Alegre, Brazil
Site 301016
Porto Alegre, Brazil
Site 301022
Recife, Brazil
Site 301009
Rio de Janeiro, Brazil
Site 301020
Santo André, Brazil
Site 301001
São José do Rio Preto, Brazil
Site 108004
Batumi, Georgia
Site 108005
Kutaisi, Georgia
Site 108011
Marneuli, Georgia
Site 108001
Tbilisi, Georgia
Site 108002
Tbilisi, Georgia
Site 108003
Tbilisi, Georgia
Site 108006
Tbilisi, Georgia
Site 108007
Tbilisi, Georgia
Site 108008
Tbilisi, Georgia
Site 108009
Tbilisi, Georgia
Site 108010
Tbilisi, Georgia
Showing 40 of 173 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.